<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01454934</url>
  </required_header>
  <id_info>
    <org_study_id>E7389-G000-302</org_study_id>
    <nct_id>NCT01454934</nct_id>
  </id_info>
  <brief_title>A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label, multicenter, Phase 3 study, comparing efficacy and safety
      of eribulin with TPC in subjects with advanced and disease progression following at least two
      prior regimens for advanced disease, which should have included a platinum-based regimen.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">May 2, 2016</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Randomization (Day 1) until date of death from any cause, or 37 months</time_frame>
    <description>The OS was defined as the time in months from the date of randomization to the date of death, regardless of cause. In the absence of confirmation of death, the participants were censored either at the date that participant was last known to be alive or the date of study cut-off, whichever was earlier. The two treatment arms were compared using the log-rank test, stratified by histology, TPC option, and geographic region; and the treatment difference between eribulin and TPC was tested at a significance level of 0.05 (2-sided). Kaplan-Meier (K-M) survival probabilities for each arm were plotted over time. The treatment effect was estimated by fitting a Cox Proportional Hazards model to the OS times including treatment arm as a factor and histology, TPC option and geographic region as strata.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST)</measure>
    <time_frame>Randomization (Day 1) until date of disease progression or death (whichever occurred first), or 37 months</time_frame>
    <description>PFS was defined as the time from the date of randomization to the date of first documentation of disease progression, or date of death, whichever occurred first. The difference in PFS (based on the tumor response evaluation as determined by the investigator) between eribulin and TPC was evaluated using the log rank test, stratified by histology, TPC option, and geographic region, tested at an alpha level of 0.05 (2-sided). PFS censoring rules will be defined in the SAP and follow Federal Department of Agriculture (FDA) guidance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Randomization (Day 1) to CR or PR</time_frame>
    <description>The ORR was defined as the proportion of participants with best overall response of complete response (CR) or partial response (PR) per RECIST criteria. The ORR was estimated by study arm based on the tumor response evaluation as determined by the investigator, according to RECIST 1.1. Participants with unknown response were treated as non-responders. The statistical difference in ORR between treatment arms was evaluated using the Cochran-Mantel-Haenszel (CMH) chi-square test with histology, TPC option, and geographic region as strata, tested at an alpha level of 0.05 (2-sided). The 95 percent confidence interval (CI) was calculated using Clopper Pearson method.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">540</enrollment>
  <condition>Non-Small Cell Lung Cancer (NSCLC)</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eribulin</intervention_name>
    <description>Administration of eribulin mesylate at a dose of 1.4 mg/m2 i.v. over 2 to 5 minutes on Days 1 and Day 8 of every cycle, where the duration of each cycle is 21 days.</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPC -Vinorelbine,Gemcitabine,Docetaxel, and Pemetrexed</intervention_name>
    <description>Vinorelbine 30 mg/m2 i.v. on Day 1, every 7 days
Gemcitabine 1250 mg/m2 i.v. on Days 1 and 8, every 21 days
Docetaxel 75 mg/m2 i.v. on Day 1 every 21 days
Pemetrexed 500 mg/m2 i.v. on Day 1 every 21 days (nonsquamous histology only).</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

        Subjects must meet all of the following criteria to be included in this study:

          1. Histologically or cytologically confirmed diagnosis of NSCLC.

          2. Documented evidence of advanced NSCLC not amenable to surgery or radiotherapy.

          3. Confirmation of the presence or absence of EGFR mutations prior to study enrolment in
             all subjects.

          4. Subjects must have received at least two prior regimens for advanced NSCLC, which
             should have included a platinum-based regimen and, in all subjects with tumors
             harbouring EGFR mutations, an EGFR TKI.

          5. Radiographic evidence of disease progression on, or after, the last anti-cancer
             regimen prior to study entry.

          6. Presence of measurable disease.

          7. ECOG performance status of 0, 1, or 2.

          8. Adequate bone marrow

          9. Adequate renal function.

         10. Adequate liver function.

         11. Female subjects of child-bearing potential must agree to use two forms of highly
             effective contraception.

         12. Male subjects and their female partners who are of child-bearing potential must agree
             to use two forms of highly effective contraception.

         13. Voluntary agreement to provide written informed consent and the willingness and
             ability to comply with all aspects of the protocol.

         14. Males or females aged at least 18 years (or any age greater than 18 years as
             determined by country legislation) at the time of informed consent.

        Exclusion:

        Subjects who meet any of the following criteria will be excluded from this study:

          1. Subjects who have received any anti-cancer therapy within 14 days, or five half-lives
             of the drug (whichever is longer), prior to randomization.

          2. Subjects who have not recovered from toxicities as a result of prior anti-cancer
             therapy to less than Grade 2.

          3. Subjects who have previously been treated, or participated in a study with eribulin,
             whether treated with eribulin or not. The TPC option must not include the same agent
             which the subject received in a prior regimen.

          4. Peripheral neuropathy more than CTCAE Grade 2.

          5. Significant cardiovascular impairment.

          6. Subjects with a high probability of Long QT Syndrome, or QTc interval &gt;500 ms.

          7. Subjects with brain or subdural metastases are not eligible, unless the metastases are
             asymptomatic and do not require treatment or have been adequately treated by local
             therapy.

          8. Any serious concomitant illness.

          9. Known HIV positive, or have an infection requiring treatment.

         10. Any malignancy that required treatment, or has shown evidence of recurrence (except
             for NSCLC, non-melanoma skin cancer, or histologically confirmed complete excision of
             carcinoma in-situ) during the 5 years prior to study entry.

         11. Female subjects must not be pregnant, and must not be breastfeeding.

         12. Hypersensitivity to either HalB or HalB chemical derivatives or both, or to any of the
             excipients of the eribulin formulation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pleasant Hill</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Port Saint Lucie</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Strasbourg</city>
        <state>Bas Rhin</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marseille Cedex 20</city>
        <state>Bouches-du-Rhone</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marseille Cedex 9</city>
        <state>Bouches-duRhone</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bordeaux</city>
        <state>Gironde</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulouse Cedex 9</city>
        <state>Haute Garonne</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Limoges</city>
        <state>Haute Vienne</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rennes Cedex 9</city>
        <state>Ille et Vilaine</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Herblain</city>
        <state>Loire Atlantique</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris Cedex 12</city>
        <state>Paris</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pierre Benite cedex</city>
        <state>Rhone</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Villejuif cedex</city>
        <state>Val de Marne</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aschaffenburg</city>
        <state>Bayern</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gauting</city>
        <state>Bayern</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Essen</city>
        <state>Nordrhein Westfalen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Koeln</city>
        <state>Nordrhein Westfalen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Recklinghausen</city>
        <state>Nordrhein Westfalen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mainz</city>
        <state>Rheinland Pfalz</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halle</city>
        <state>Sachsen Anhalt</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lido di Camaiore</city>
        <state>Lucca</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monza</city>
        <state>Milano</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aviano</city>
        <state>Pordenone</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cremona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi-Ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kashiwa-shi</city>
        <state>Chiba-Ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka-Ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hiroshima-shi</city>
        <state>Hiroshima-Ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kobe-shi</city>
        <state>Hygo-Ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Akashi-shi</city>
        <state>Hyogo-ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sendai-shi</city>
        <state>Miyagi-Ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nigata-shi</city>
        <state>Nigata-Ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kurashiki-shi</city>
        <state>Okayama-Ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Habinko-shi</city>
        <state>Osaka-Fu</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka-Fu</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osakasayama-shi</city>
        <state>Osaka-Fu</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sunto-gun</city>
        <state>Shizuoka-Ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo-to</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Koto-ku</city>
        <state>Tokyo-To</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ube-shi</city>
        <state>Yamaguchi-Ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kitaadachi-gun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suwon</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mrozy</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Otwock</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sczedin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warsazawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barnaul</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2011</study_first_submitted>
  <study_first_submitted_qc>October 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2011</study_first_posted>
  <results_first_submitted>January 11, 2017</results_first_submitted>
  <results_first_submitted_qc>January 11, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 1, 2017</results_first_posted>
  <last_update_submitted>August 3, 2017</last_update_submitted>
  <last_update_submitted_qc>August 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm A: Erubulin Mesilate</title>
          <description>Eribulin mesilate (1.4 mg/m2) was administered intravenously (IV) over 2 to 5 minutes on Day 1 and Day 8 of every cycle, where the duration of each cycle is 21 days.</description>
        </group>
        <group group_id="P2">
          <title>Arm B: Vinorelbine, Gemcitabine, Docetaxel, or Pemetrexed</title>
          <description>Treatment of Physician's Choice (TPC): Vinorelbine (30 mg/m2) was administered IV on Day 1 every 7 days, Gemcitabine (1250 mg/m2) was administered IV on Days 1 and 8 every 21 days (or 1000 mg/m2 IV on Days 1, 8, and 15 every 28 days), Docetaxel (75 mg/m2) was administered IV on Day 1 every 21 days, or Pemetrexed (500 mg/m2 ) was administered IV on Day 1 every 21 days (nonsquamous histology only).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="270"/>
                <participants group_id="P2" count="270"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="270"/>
                <participants group_id="P2" count="270"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="194"/>
                <participants group_id="P2" count="180"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawn consent</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Clinical progression</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ongoing, survival follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set included all randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Arm A: Erubulin Mesilate</title>
          <description>Eribulin mesilate (1.4 mg/m2) was administered intravenously (IV) over 2 to 5 minutes on Day 1 and Day 8 of every cycle, where the duration of each cycle is 21 days.</description>
        </group>
        <group group_id="B2">
          <title>Arm B: Vinorelbine, Gemcitabine, Docetaxel, or Pemetrexed</title>
          <description>Treatment of Physician's Choice (TPC): Vinorelbine (30 mg/m2) was administered IV on Day 1 every 7 days, Gemcitabine (1250 mg/m2) was administered IV on Days 1 and 8 every 21 days (or 1000 mg/m2 IV on Days 1, 8, and 15 every 28 days), Docetaxel (75 mg/m2) was administered IV on Day 1 every 21 days, or Pemetrexed (500 mg/m2 ) was administered IV on Day 1 every 21 days (nonsquamous histology only).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="270"/>
            <count group_id="B2" value="270"/>
            <count group_id="B3" value="540"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.4" spread="9.62"/>
                    <measurement group_id="B2" value="60.8" spread="9.32"/>
                    <measurement group_id="B3" value="61.1" spread="9.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="208"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="163"/>
                    <measurement group_id="B2" value="169"/>
                    <measurement group_id="B3" value="332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival (OS)</title>
        <description>The OS was defined as the time in months from the date of randomization to the date of death, regardless of cause. In the absence of confirmation of death, the participants were censored either at the date that participant was last known to be alive or the date of study cut-off, whichever was earlier. The two treatment arms were compared using the log-rank test, stratified by histology, TPC option, and geographic region; and the treatment difference between eribulin and TPC was tested at a significance level of 0.05 (2-sided). Kaplan-Meier (K-M) survival probabilities for each arm were plotted over time. The treatment effect was estimated by fitting a Cox Proportional Hazards model to the OS times including treatment arm as a factor and histology, TPC option and geographic region as strata.</description>
        <time_frame>Randomization (Day 1) until date of death from any cause, or 37 months</time_frame>
        <population>Full analysis set included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Erubulin Mesilate</title>
            <description>Eribulin mesilate (1.4 mg/m2) was administered intravenously (IV) over 2 to 5 minutes on Day 1 and Day 8 of every cycle, where the duration of each cycle is 21 days.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Vinorelbine, Gemcitabine, Docetaxel, or Pemetrexed</title>
            <description>Treatment of Physician's Choice (TPC): Vinorelbine (30 mg/m2) was administered IV on Day 1 every 7 days, Gemcitabine (1250 mg/m2) was administered IV on Days 1 and 8 every 21 days (or 1000 mg/m2 IV on Days 1, 8, and 15 every 28 days), Docetaxel (75 mg/m2) was administered IV on Day 1 every 21 days, or Pemetrexed (500 mg/m2 ) was administered IV on Day 1 every 21 days (nonsquamous histology only).</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>The OS was defined as the time in months from the date of randomization to the date of death, regardless of cause. In the absence of confirmation of death, the participants were censored either at the date that participant was last known to be alive or the date of study cut-off, whichever was earlier. The two treatment arms were compared using the log-rank test, stratified by histology, TPC option, and geographic region; and the treatment difference between eribulin and TPC was tested at a significance level of 0.05 (2-sided). Kaplan-Meier (K-M) survival probabilities for each arm were plotted over time. The treatment effect was estimated by fitting a Cox Proportional Hazards model to the OS times including treatment arm as a factor and histology, TPC option and geographic region as strata.</description>
          <population>Full analysis set included all randomized participants.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="270"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" lower_limit="7.4" upper_limit="11.4"/>
                    <measurement group_id="O2" value="9.5" lower_limit="8.5" upper_limit="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>OS was compared between eribulin and TPC testing the following null hypothesis: H0: OS in Arm A (eribulin) is equal to OS in Arm B (TPC) against the alternative: H1: OS in Arm A (eribulin) is not equal to OS in Arm B (TPC)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1343</p_value>
            <p_value_desc>P-value was calculated from a 2-sided long-rank test stratified by histology, TPC option, and geographic region.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.41</ci_upper_limit>
            <estimate_desc>Hazard Ratio was based on a Cox regression model including treatment as covariate, and histology, TPC option and geographic region as strata.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST)</title>
        <description>PFS was defined as the time from the date of randomization to the date of first documentation of disease progression, or date of death, whichever occurred first. The difference in PFS (based on the tumor response evaluation as determined by the investigator) between eribulin and TPC was evaluated using the log rank test, stratified by histology, TPC option, and geographic region, tested at an alpha level of 0.05 (2-sided). PFS censoring rules will be defined in the SAP and follow Federal Department of Agriculture (FDA) guidance.</description>
        <time_frame>Randomization (Day 1) until date of disease progression or death (whichever occurred first), or 37 months</time_frame>
        <population>Full analysis set included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Erubulin Mesilate</title>
            <description>Eribulin mesilate (1.4 mg/m2) was administered intravenously (IV) over 2 to 5 minutes on Day 1 and Day 8 of every cycle, where the duration of each cycle is 21 days.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Vinorelbine, Gemcitabine, Docetaxel, or Pemetrexed</title>
            <description>Treatment of Physician's Choice (TPC): Vinorelbine (30 mg/m2) was administered IV on Day 1 every 7 days, Gemcitabine (1250 mg/m2) was administered IV on Days 1 and 8 every 21 days (or 1000 mg/m2 IV on Days 1, 8, and 15 every 28 days), Docetaxel (75 mg/m2) was administered IV on Day 1 every 21 days, or Pemetrexed (500 mg/m2 ) was administered IV on Day 1 every 21 days (nonsquamous histology only).</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST)</title>
          <description>PFS was defined as the time from the date of randomization to the date of first documentation of disease progression, or date of death, whichever occurred first. The difference in PFS (based on the tumor response evaluation as determined by the investigator) between eribulin and TPC was evaluated using the log rank test, stratified by histology, TPC option, and geographic region, tested at an alpha level of 0.05 (2-sided). PFS censoring rules will be defined in the SAP and follow Federal Department of Agriculture (FDA) guidance.</description>
          <population>Full analysis set included all randomized participants.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="270"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="2.6" upper_limit="3.9"/>
                    <measurement group_id="O2" value="2.8" lower_limit="2.6" upper_limit="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>OS was compared between eribulin and TPC testing the following null hypothesis: H0: OS in Arm A (eribulin) is equal to OS in Arm B (TPC) against the alternative: H1: OS in Arm A (eribulin) is not equal to OS in Arm B (TPC)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3946</p_value>
            <p_value_desc>P-value was calculated from a 2-sided long-rank test stratified by histology, TPC option, and geographic region.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.32</ci_upper_limit>
            <estimate_desc>The hazard ratio was based on a Cox regression model including treatment as covariate, and histology, TPC option, and geographic region as strata.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate (ORR)</title>
        <description>The ORR was defined as the proportion of participants with best overall response of complete response (CR) or partial response (PR) per RECIST criteria. The ORR was estimated by study arm based on the tumor response evaluation as determined by the investigator, according to RECIST 1.1. Participants with unknown response were treated as non-responders. The statistical difference in ORR between treatment arms was evaluated using the Cochran-Mantel-Haenszel (CMH) chi-square test with histology, TPC option, and geographic region as strata, tested at an alpha level of 0.05 (2-sided). The 95 percent confidence interval (CI) was calculated using Clopper Pearson method.</description>
        <time_frame>Randomization (Day 1) to CR or PR</time_frame>
        <population>Full analysis set included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Erubulin Mesilate</title>
            <description>Eribulin mesilate (1.4 mg/m2) was administered intravenously (IV) over 2 to 5 minutes on Day 1 and Day 8 of every cycle, where the duration of each cycle is 21 days.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Vinorelbine, Gemcitabine, Docetaxel, or Pemetrexed</title>
            <description>Treatment of Physician's Choice (TPC): Vinorelbine (30 mg/m2) was administered IV on Day 1 every 7 days, Gemcitabine (1250 mg/m2) was administered IV on Days 1 and 8 every 21 days (or 1000 mg/m2 IV on Days 1, 8, and 15 every 28 days), Docetaxel (75 mg/m2) was administered IV on Day 1 every 21 days, or Pemetrexed (500 mg/m2 ) was administered IV on Day 1 every 21 days (nonsquamous histology only).</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR)</title>
          <description>The ORR was defined as the proportion of participants with best overall response of complete response (CR) or partial response (PR) per RECIST criteria. The ORR was estimated by study arm based on the tumor response evaluation as determined by the investigator, according to RECIST 1.1. Participants with unknown response were treated as non-responders. The statistical difference in ORR between treatment arms was evaluated using the Cochran-Mantel-Haenszel (CMH) chi-square test with histology, TPC option, and geographic region as strata, tested at an alpha level of 0.05 (2-sided). The 95 percent confidence interval (CI) was calculated using Clopper Pearson method.</description>
          <population>Full analysis set included all randomized participants.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="270"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" lower_limit="8.6" upper_limit="16.7"/>
                    <measurement group_id="O2" value="15.2" lower_limit="11.1" upper_limit="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>OS was compared between eribulin and TPC testing the following null hypothesis: H0: OS in Arm A (eribulin) is equal to OS in Arm B (TPC) against the alternative: H1: OS in Arm A (eribulin) is not equal to OS in Arm B (TPC)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3034</p_value>
            <p_value_desc>The P-value was stratified by histology, TPC option, and geographic region.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse events (AEs) and serious adverse events (SAEs) were collected from the first dose of study treatment to thirty days after final dose of study medication. Participants were followed for approximately 37 months.</time_frame>
      <desc>Safety analysis set included all randomized participants who received at least one dose of study treatment. AEs were graded on a 5-point scale according to Common Terminology for Adverse Events (CTCAE) version 4.0. All AEs graded 4 or 5 were considered serious.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm A: Erubulin Mesilate</title>
          <description>Eribulin mesilate (1.4 mg/m2) was administered intravenously (IV) over 2 to 5 minutes on Day 1 and Day 8 of every cycle, where the duration of each cycle is 21 days.</description>
        </group>
        <group group_id="E2">
          <title>Arm B: Vinorelbine, Gemcitabine, Docetaxel, or Pemetrexed</title>
          <description>Treatment of Physician's Choice (TPC): Vinorelbine (30 mg/m2) was administered IV on Day 1 every 7 days, Gemcitabine (1250 mg/m2) was administered IV on Days 1 and 8 every 21 days (or 1000 mg/m2 IV on Days 1, 8, and 15 every 28 days), Docetaxel (75 mg/m2) was administered IV on Day 1 every 21 days, or Pemetrexed (500 mg/m2 ) was administered IV on Day 1 every 21 days (nonsquamous histology only).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Febrile bone marrow aplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Coronary artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Large intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Oesophageal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Oesophageal varices haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Wound infection fungal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Ilium fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Polydipsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Malignant ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Metastases to meninges</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Metastatic pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Embolic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Monoplegia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Fear</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pharyngeal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Jugular vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Superior vena cava syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Superior vena caval stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="264" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="265" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Muscular Weakness</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eisai Medical Services</name_or_title>
      <organization>Eisai Inc.</organization>
      <phone>1-888-422-4743</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

